

Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Immunotherapeutics Committee

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Robin Kamucheka
 Clinical Trial Program Manager: Sharon Palmer

Time/Location

Friday, May 1, 2026 8:30 a.m. - 10:30 a.m.
 Room: Seacliff CD (Bay Level)

Agenda

8:30 - 8:35 am Welcome & Immunotherapeutics Committee Update
 Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

8:35 – 8:50 am iMATCH Pilot Update: Stage II Update
 Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan
S2101 Study Chairs

8:50 – 8:55 am Q & A

8:55 – 9:10 am Inferring Tumor Immune Activity ('hotness') and
 Immunotherapy Response Directly from the H&E
 Slides - Eytan Ruppim, MD, PhD, *Cedars-Sinai Medical
 Center*

9:10 – 9:25 am Alliance Immunotherapeutics Update
 Elad Sharon, MD, MPH
*Associate Professor of Medicine
 Dana Farber Cancer Institute*

9:25 – 9:30 am Q & A

9:30 – 9:45 am ECOG-ACRIN Immunotherapeutics Update
 Yana G. Najjar, MD
*Associate Professor of Medicine, University of Pittsburgh,
 Director, Clinical and Translational Research Center*

9:45 – 9:50 am Q & A

9:50 – 10:05 am NRG Immunotherapeutics Update
 Susanna V Ulahannan, MD
*Associate Professor of Medicine, University of
 Oklahoma Health, Director Oklahoma TSET Phase 1
 Program*

10:05 – 10:10 am Cancer Immune Monitoring and Analysis Center
 (CIMAC) Update - Gheath Alatrash, MD
*Associate Professor, University of Texas MD Anderson
 Cancer Center, MDA CIMAC Co-Lead*

10:10 – 10:15 am Q & A

10:15 – 10:30 am Final Comments & Closing Remarks
 Siwen Hu-Lieskovan & Katerina Politi
SWOG Immunotherapeutics Committee Co-Chairs

Active Studies

S2101, "Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22.

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

Immunotherapeutics Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	<i>S2101</i>
<i>Essentia Health NCI Community Oncology Research Program</i>	1
<i>Froedtert and the Medical College of Wisconsin LAPS</i>	5
<i>Heartland Cancer Research NCORP</i>	1
<i>Michigan Cancer Research Consortium NCORP</i>	1
<i>New Mexico Minority Underserved NCORP</i>	1
<i>Northwestern University LAPS</i>	1
<i>Pacific Cancer Research Consortium NCORP</i>	1
<i>Regents of the University of Michigan</i>	15
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	2
<i>University of Arkansas for Medical Sciences</i>	2
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	12
<i>ALLIANCE</i>	13
<i>ECOG-ACRIN</i>	11
<i>NRG</i>	10
<i>Total</i>	<i>76</i>

